TNXP vs. AVTX, NNVC, MIRA, RDHL, TRAW, IMNN, PPBT, ABVC, EDSA, and AGE
Should you be buying Tonix Pharmaceuticals stock or one of its competitors? The main competitors of Tonix Pharmaceuticals include Avalo Therapeutics (AVTX), NanoViricides (NNVC), MIRA Pharmaceuticals (MIRA), RedHill Biopharma (RDHL), Traws Pharma (TRAW), Imunon (IMNN), Purple Biotech (PPBT), ABVC BioPharma (ABVC), Edesa Biotech (EDSA), and AgeX Therapeutics (AGE). These companies are all part of the "pharmaceutical preparations" industry.
Tonix Pharmaceuticals (NASDAQ:TNXP) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation, dividends and community ranking.
Tonix Pharmaceuticals has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.
Tonix Pharmaceuticals received 334 more outperform votes than Avalo Therapeutics when rated by MarketBeat users. Likewise, 64.20% of users gave Tonix Pharmaceuticals an outperform vote while only 31.25% of users gave Avalo Therapeutics an outperform vote.
Avalo Therapeutics has lower revenue, but higher earnings than Tonix Pharmaceuticals. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Tonix Pharmaceuticals presently has a consensus price target of $5.50, indicating a potential upside of 3,407.65%. Given Tonix Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Tonix Pharmaceuticals is more favorable than Avalo Therapeutics.
In the previous week, Avalo Therapeutics had 1 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 3 mentions for Avalo Therapeutics and 2 mentions for Tonix Pharmaceuticals. Avalo Therapeutics' average media sentiment score of 0.64 beat Tonix Pharmaceuticals' score of 0.00 indicating that Avalo Therapeutics is being referred to more favorably in the news media.
Tonix Pharmaceuticals has a net margin of 0.00% compared to Avalo Therapeutics' net margin of -1,639.50%. Tonix Pharmaceuticals' return on equity of -87.67% beat Avalo Therapeutics' return on equity.
82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 0.5% of Tonix Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of Avalo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Tonix Pharmaceuticals beats Avalo Therapeutics on 13 of the 18 factors compared between the two stocks.
Get Tonix Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TNXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tonix Pharmaceuticals Competitors List
Related Companies and Tools
